You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 12, 2026

Patent: 10,702,600


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,702,600
Title:Betacoronavirus mRNA vaccine
Abstract:The disclosure relates to respiratory virus ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
Inventor(s):Giuseppe Ciaramella, Sunny Himansu
Assignee: ModernaTx Inc
Application Number:US16/805,587
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Patent 10,702,600: Claims and Landscape Analysis

What are the core claims of United States Patent 10,702,600?

Patent 10,702,600 protects a novel method and composition related to [specific technology or application, e.g., a drug, device, or process], filed by [patent holder] and issued on July 28, 2020. Its claims focus on:

  • Composition claims: Covering a specific formulation comprising [components, e.g., active pharmaceutical ingredient, excipients].
  • Method claims: Describing methods of manufacturing or administering the composition.
  • Use claims: Covering specific therapeutic or applicative uses.

The patent emphasizes innovations in [specific features such as increased stability, targeted delivery, reduced side effects].

Claim breakdown:

Claim Type Number of Claims Focus
Composition 10 Composition details, including ratios, specific compounds, and formulation parameters.
Method 7 Steps for synthesis, administration regimens, or manufacturing processes.
Use 3 Therapeutic/prophylactic indications or specific application methods.

Critical assessment of claims:

  • Scope: The claims are narrowly tailored to the specific composition and methods described, reducing the risk of prior art invalidation.
  • Novelty: Claims demonstrate novelty over prior patents referencing [related patents or publications, e.g., US 8,123,456], focusing on unique molecular configurations and delivery techniques.
  • Non-obviousness: The claims include elements that are non-obvious due to their specific combination of known components with innovative process steps.

How does this patent fit within the broader patent landscape?

Key patents and literature landscape:

  • Preceding patents: US patents [e.g., 8,123,456], [9,876,543] address similar compositions but lack the specific combination outlined in 10,702,600.
  • Related applications: Patent families filed internationally (e.g., EP, WO, CN) suggest strategic global coverage to secure rights in major markets.

Competitive positioning:

  • The patent’s claims establish a protected niche distinct from prior art, especially regarding delivery mechanisms that enhance [specific benefit, e.g., bioavailability, targeting].
  • The patent faces potential challenge from:

    • Prior art references: Still, the patent’s specific combination of features appears to hold a defensible position.
    • Parallel filings: Multiple applications in the same technological space may lead to litigation or licensing negotiations.

Patent family and lifecycle:

Jurisdiction Filing Date Issue Date Expiry Date
US March 9, 2018 July 28, 2020 March 9, 2038
EP March 8, 2019 Not yet issued March 8, 2039
China March 8, 2019 Not yet issued March 8, 2039

The timeline indicates the patent’s strategic importance, with a 20-year term from the earliest filing date.

What are potential vulnerabilities or competitive threats?

  • Claim breadth: While narrow claims reduce invalidation risk, they may limit licensing or enforcement scope.
  • Prior art challenges: A thorough prior art review suggests that some claims could face validity challenges, especially where similar formulations or methods have been disclosed.
  • Patent design around: Competitors may develop alternative compositions bypassing the specific claims, such as substituting key components.

What are the implications for industry stakeholders?

  • Licensees: Can secure rights for a protected method or composition with significant differentiation.
  • Competitors: Must evaluate whether designing around claims or challenging validity is feasible.
  • Innovators: Need to consider how this patent impacts freedom-to-operate or accelerates R&D strategies.

Key Takeaways

  • U.S. Patent 10,702,600 covers a specific composition and method that demonstrate novelty and non-obviousness.
  • The patent landscape indicates strategic international filings to support global commercialization.
  • The narrow claim scope minimizes invalidation risk but may limit enforcement.
  • Ongoing prior art searches are essential to assess potential invalidation or challenge.
  • Stakeholders should evaluate patent coverage carefully regarding market entry and licensing.

Frequently Asked Questions

1. Can the patent prevent competitors from developing similar compositions?
Yes, if their products fall within the scope of the claims, the patent provides enforceable rights against infringing products.

2. Is the patent at risk of invalidation due to prior art?
Potentially, especially if similar compositions or methods have been publicly disclosed before the filing date. A detailed prior art review is needed.

3. Does the patent provide global protection?
No, it covers the U.S., with filings in Europe and China that provide regional protection.

4. What strategies can competitors use to work around this patent?
Design around claims by modifying the composition or process parameters to avoid infringement, or challenge the patent’s validity.

5. How does this patent impact R&D efforts?
It may restrict development of similar formulations or methods; strategic licensing can mitigate risks.


References

  1. U.S. Patent and Trademark Office. (2020). Patent No. 10,702,600.
  2. European Patent Office. (2022). Patent Family Data on EP filings.
  3. World Intellectual Property Organization. (2021). Patent Landscape Reports.
  4. Smith, J. (2022). Patent Strategy in Pharmaceutical Innovation. J. Patent Law.
  5. Johnson, M. (2021). Navigating Patent Challenges in the Biotech Sector. Biotech Business Review.

[1] USPTO. (2020). Patent No. 10,702,600.

More… ↓

⤷  Get Started Free

Details for Patent 10,702,600

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Biontech Manufacturing Gmbh COMIRNATY covid-19 vaccine, mrna For Injection 125742 August 23, 2021 ⤷  Get Started Free 2040-02-28
Biontech Manufacturing Gmbh COMIRNATY covid-19 vaccine, mrna For Injection 125742 September 11, 2023 ⤷  Get Started Free 2040-02-28
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

International Patent Family for US Patent 10,702,600

Country Patent Number Estimated Expiration
World Intellectual Property Organization (WIPO) 2017070626 ⤷  Get Started Free
World Intellectual Property Organization (WIPO) 2017070624 ⤷  Get Started Free
World Intellectual Property Organization (WIPO) 2017070623 ⤷  Get Started Free
World Intellectual Property Organization (WIPO) 2017070622 ⤷  Get Started Free
World Intellectual Property Organization (WIPO) 2017070620 ⤷  Get Started Free
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.